Family Medicine Doctors in Washington, MI Accepting Medicare

7 Family Medicine doctors found. Showing 1 - 7

Dr. Jennifer Carlton, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 64580 Van Dyke Rd Ste C, Washington, MI 48095 Phone: 586-752-9629

Brigitte K Stern, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 64580 Van Dyke Rd, Suite C, Washington, MI 48095 Phone: 586-752-9629    Fax: 586-752-4099

Timothy James Blanchet, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 64580 Van Dyke Rd, Suite C, Washington, MI 48095 Phone: 586-752-9483    Fax: 586-752-4099

Curtis Patrick Craig, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 64580 Van Dyke Rd, Suite C, Washington, MI 48095 Phone: 586-752-9629    Fax: 586-752-4099

Bruce Edward Carl, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 64580 Van Dyke Rd, Suite C, Washington, MI 48095 Phone: 586-752-9629    Fax: 586-752-4099

Dr. Gary Frank Curatolo, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 64521 Van Dyke Rd, Washington, MI 48095 Phone: 586-752-6535    Fax: 586-752-1840

Dr. David Calton, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 67150 Van Dyke Rd, Suite 200, Washington, MI 48095 Phone: 586-336-7321    Fax: 586-336-7356

News Archive

Viewpoints: Iowa 'botched' high risk pool; Clinton praises Family and Medical Leave Act; HHS contraceptive policy's 'sensible balance'

The health reform law will get millions of Americans coverage in 2014. Until then, Congress offered Iowa up to $35 million to provide temporary insurance for people whose health prevent them from buying coverage on their own. Iowa botched the entire concept behind the high-risk pool, and state and federal officials stood by and failed to take corrective action.

FDA approves clinical studies of novel anti-cancer drug developed by Italian researchers

Nerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct for the first time clinical trials of a novel antitumoral agent.

Experts share tips on prevention of prostate cancer

Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually.

Imatinib mesylate (Gleevec) inhibits important pathways that spur cancer growth

A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

Study helps explain why some people contract bacterial super-infections

A recent study published in the July issue of the Journal of Immunology helps explain why some humans contract bacterial super-infections like pneumonia with influenza. The research was led by Le Bonheur Pediatrician-in-Chief Jon McCullers, MD - an infectious disease specialist who is also chair of the Department of Pediatrics for the University of Tennessee Health Science Center and adjunct faculty at St. Jude Children's Research Hospital.

Read more Medical News

› Verified 1 days ago